Study Objective: Obstructive sleep apnea is prevalent among people with asthma, but underlying mechanisms remain unknown. Inhaled corticosteroids may contribute. We tested the effects of orally inhaled fl uticasone propionate (FP) on upper airway (UAW) during sleep and wakefulness. Study design: 16-week single-arm study. Participants: 18 (14 females, mean [ ± SD] age 26 ± 6 years) corticosteroid-naïve subjects with mild asthma (FEV 1 89 ± 8% predicted). Interventions: High dose (1,760 mcg/day) inhaled FP. Measurements: (1) UAW collapsibility (passive critical closing pressure [Pcrit]); (2) tongue strength (maximum isometric pressure-Pmax, in KPa) and endurance-time (in seconds) able to maintain 50% Pmax across 3 trials (Ttot)-at anterior and posterior locations; (3) fat fraction and volume around UAW, measured by magnetic resonance imaging in three subjects. Results: Pcrit overall improved (became more negative) (mean ± SE) (-8.2 ± 1.1 vs. -12.2 ± 2.2 cm H 2 O, p = 0.04); the response was dependent upon baseline characteristics, with older, male gender, and worse asthma control predicting Pcrit deterioration (less negative). Overall, Pmax increased (anterior p = 0.02; posterior p = 0.002), but Ttot generally subsided (anterior p = 0.0007; posterior p = 0.06), unrelated to Pcrit response. In subjects studied with MRI, fat fraction and volume increased by 20.6% and 15.4%, respectively, without Pcrit changes, while asthma control appeared improved. Conclusions: In this study of young, predominantly female, otherwise healthy subjects with well-controlled asthma and stiff upper airways, 16-week high dose FP treatment elicited Pcrit changes which may be dependent upon baseline characteristics, and determined by synchronous and reciprocally counteracting local and lower airway effects. The long-term implications of these changes on sleep disordered breathing severity remain to be determined. 
asthma patients have a unique set of predisposing characteristics related to the pathophysiology of asthma itself, its comorbidities and treatment with corticosteroids. 9, 10 The association of OSA with corticosteroids was initially suggested by the high prevalence of OSA (50%) observed in patients with Cushing's, conditions characterized by sustained hypercortisolism. 11 Also, more severe OSA was reported in patients with difficult-to-control asthma requiring continuous versus bursts of oral corticosteroids. 8 In our clinic survey of 244 asthma patients, we found that inhaled corticosteroid (ICS) therapy was associated with a dose-dependent increase in the risk of habitual snoring and OSA, independent of asthma severity, and other known risk factors, including excess weight. 12 While the available literature on the association of OSA and corticosteroid use is limited by cross-sectional designs, collectively, these studies raise the possibility that ICS treatment may negatively affect the dynamic between the upper and lower airway, rendering people with asthma vulnerable to OSA.
Myopathy and weight gain/centripetal fat redistribution are known side effects of corticosteroids. ICS are known to cause dysphonia which has been attributed to myopathic changes of the vocal cord adductors and occurs dose-dependently. 13 It is possible that ICS therapy may deleteriously influence pharyngeal upper airway (UAW) patency by: (1) producing myopathy of its dilators, particularly the genioglossus, analogous to the myopathy of vocal cord adductors, and (2) weight gain/fat redistribution to the neck area, owing to their systemic absorption. 14 Dilator muscle dysfunction may be problematic, particularly in the face of narrowed UAW by enhanced extraluminal fat-imposed pressure. All these anatomical and mechanical deficiencies could render the UAW more vulnerable to occlusion during sleep, predisposing to OSA.
Fluticasone propionate (FP) is the most potent 14 and most commonly prescribed ICS to treat asthma. We aimed to test the effects of inhaled FP on UAW collapsibility during sleep, and to assess tongue function changes and fat redistribution around UAW as potential underlying mechanisms. We hypothesized that inhaled FP would: (1) increase UAW collapsibility during sleep; (2) be associated with reduced wakefulness tongue strength and endurance and increased fat content around UAW structures. Preliminary results of this study were published in abstract form. 15 
METHODS

Subjects
Subjects aged 18-65 years with a history of asthma were recruited from University of Wisconsin (UW) Allergy/Asthma/ Pulmonary Research database. The inclusion and exclusion criteria are presented in the supplemental material. The protocol was IRB-approved and all subjects signed informed consent (Registered: www.clinicaltrials.gov: NCT01184118).
Study Design
This was a prospective, single group and center study (Figure 1) . After the baseline studies, subjects initiated 16-week treatment with inhaled FP metered dose inhaler (MDI) (GlaxoSmithKline, NC), 220 mcg/inhalation, 4 inhalations twice/day. Adherence to medication was electronically *Visits for phenotyping/eligibility assessment.
† Asthma control was assessed with the Asthma Control Questionnaire (ACQ), standardized asthma quality of life questionnaire (AQLQs), spirometry and diaries (except at V2).
‡ Questionnaires included: 1) the Sleep Apnea scale of the Sleep Disorders Questionnaire (SA-SDQ), 2) Pittsburgh Sleep Quality Index (PSQI), and 3) Epworth Sleepiness Scale (ESS). Scans were obtained in the last three subjects. V, visit; Pcrit, critical closing pressure of the upper airway; MRI, magnetic resonance imaging; FP, inhaled fluticasone propionate; MDI, metered dose inhaler; LSE, lingual strength and endurance, measured using the Iowa Oral Performance Instrument; ACQ, Asthma Control Questionnaire (symptoms and rescue use) which was administered via phone.
recorded via DOSER (Meditrack Products, MA). Only subjects with an initial 2-week dosing adherence ≥ 75% continued in the protocol. The treatment phase was followed by a 4-week run-out, to step down FP dose (see supplemental material), with subsequent transition to clinical care.
Outcomes Measures
The primary outcome was UAW collapsibility, as measured by passive critical closing pressure (Pcrit) during sleep. Secondary outcomes were wakefulness tongue strength and endurance, OSA risk measured by the Sleep Apnea scale of the Sleep Disorders Questionnaire (SA-SDQ), 16 Epworth Sleepiness Scale (ESS), 17 and Pittsburgh Sleep Quality Index (PSQI). 18 Due to a new funding opportunity that became available late in the study, only the last 3 subjects could undergo UAW magnetic resonance imaging (MRI). Asthma control was monitored with the Asthma Control Questionnaire (ACQ-version with symptoms and rescue bronchodilator use), 19 spirometry (FEV 1 % predicted) 20 and standardized Asthma Quality of Life Questionnaire (AQLQs). 21 The ranges, validated discriminative cutoffs and interpretations of the questionnaires are presented in the legends of Tables 1 and  2 . Subjects also kept a diary of daytime and nighttime symptoms, rescue β 2 -agonist use, and peak expiratory flows (PEF).
Experimental Protocol for Polysomnogram (PSG) and Pcrit Studies
A standard montage was used for the PSG 22 performed only at baseline; for Pcrit studies, we used a set-up analogous to our previous report 23 (see supplemental material). , forced expiratory flow between 25% and 75% of vital capacity; PC20, the provocative concentration of methacholine, necessary to produce a 20% fall in FEV 1 ; AQLQ(s), standardized version of the Asthma Quality of Life Questionnaire; LABA, long acting β 2 -agonist. *Scores on the ACQ range from 0 to 6, with a higher score indicating worse asthma control; the minimal clinically important difference (MID) is 0.5. 19 † Scores on the AQLQ(s) range from 1 to 7, with a higher score indicating a better quality of life; the MID is 0.5. 
Lingual Strength and Endurance (LSE) Assessment
Measurements were performed at anterior and posterior locations, as previously published (see supplemental material). 24 Tongue strength was determined as the maximum pressure (in KiloPascals) generated during an isometric task (Pmax). Endurance was determined as the time (in seconds) subjects maintained 50% of the Pmax obtained at each visit; as previously reported, 25 3 trials were obtained at each location and 2 endurance indices were generated: (1) the duration of the first trial (T 1 ), and (2) the total time of all 3 trials (T tot = T1 + T2 + T3).
Magnetic Resonance Imaging
High-resolution anatomic images progressing from the roof of the hard palate to the tip of the epiglottis 26 were acquired using the Iterative Decomposition of water and fat with echo asymmetry and least squares estimation fast spin-echo (IDEAL-FSE) method, 27 to allow in vivo determination of total fat volume and fat fraction in the structures surrounding the pharyngeal UAW (see supplemental material for details). Scans were obtained on 3 participants.
Data Analysis
Sleep and Pcrit data were analyzed using established criteria (see supplemental material). 22, 23 Details on MRI data analysis are also presented in the supplemental material.
Statistical analyses were performed using SAS software, version 9.3 (SAS Institute, NC). Descriptive data are expressed as mean ± standard deviation (SD) for continuous variables, and percentages for categorical variables (Tables 1 and 2 ). Mean ± standard errors (SE) are presented in the text and where statistical comparisons are being made in Figures 3-5 and Tables 3-5. Pearson tests were used to assess correlations as needed. Changes in Pcrit were analyzed with a paired t-test. Using the Pcrit change cutoff of ≥ 3 cm H 2 O, proposed as the minimally significant change necessary to assess the effect of an intervention, 28 subjects were divided in 3 subgroups: improved (more negative Pcrit), unchanged, or worsened (less negative). To compare these groups on baseline and change in time in continuous and categorical variables, univariate generalized linear models with post hoc contrast statements (with adjustment within each model for multiple pairwise comparisons using the studentized maximum modulus method 29 ) and Fisher exact tests, respectively, were used. Paired-t tests were used to compare changes from baseline in variables of interest for the subjects who underwent MRI scanning.
The other measurements, which were collected at multiple time-points were analyzed separately, for the main treatment and for the run-out period, using mixed-effects linear models with visit number as the fixed within subject factor of interest.
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For the run-out, percent reduction in cumulative FP dose used relative to the treatment period was included as a covariate. Relationships between changes in Pcrit and other variables were tested using linear regression models. McNemar test was used to assess changes in categorical variables. 31 Two-sided p-values < 0.05 indicated statistical significance.
RESULTS
The study flow chart is presented in Figure 2 . Eighteen subjects completed the full protocol, and the last 3 subjects also underwent MRI studies. Table 2 . On average, subjects were young, predominantly female, slightly overweight, with well-controlled asthma symptoms, without significant lower airways obstruction, and without controller therapy. They had stiff UAWs, minimal sleep disordered breathing (SDB) (none had OAI > 10 events/h or desaturation < 70%), and normal ESS and PSQI scores.
Baseline Characteristics
Changes in Pcrit and Predictors of Response during the Treatment Phase
The overall FP dosing adherence was (mean ± SE) 91.2% ± 1.7%. Table 3 presents the changes in asthma control indices, which as expected, improved significantly with treatment. Figure 3 depicts the change in Pcrit with FP treatment. In contrast to our hypothesis, overall, Pcrit improved (became more negative) from -8.2 ± 1.1 at baseline to -12.2 ± 2.2 cm H 2 O (mean change -4.00 with 95% CI [-7.73, -0.23], p = 0.04, supplemental material, Table S2 ). However, as noted (Figure 3) , the response was variable, and when stratified by a change ≥ 3 cm H 2 O, 8 subjects significantly improved (Pcrit change: -10.02 ± 2.68 cm H 2 O, p = 0.007), 8 remained unchanged (0.08 ± 0.50, p = 0.88), and 2 worsened (4.0 ± 0.30, p = 0.047). Comparison of baseline characteristics between these subgroups identified older age, male gender, and worse asthma control (by ACQ) as predictors of deterioration in Pcrit (Table 4 ) with both subjects in this latter subgroup having all 3 characteristics. Trends in other baseline variables, such as higher BMI, larger necks, worse SDB (RDI, minimum SpO 2 ), and FEV 1 (% of predicted) and more frequent habitual and 5B) and posterior locations ( Figures 5C and 5D) .
The subgroups of Pcrit responses showed no differences in baseline tongue parameters ( Table 4 ) or in their changes with treatment ( Table 5 ). Similar to above Pcrit changes, the holding pressure increased in the subgroup whose Pcrit worsened vs. those who improved (p = 0.03). No differential subgroup responses were noted in the other variables recorded, including asthma control indices, scores on sleep questionnaires, and anthropometrics ( Table 5) .
Magnetic Resonance Imaging Results
The last 3 consecutive subjects (all females, 22 ± 1 year old) underwent upper airway MRI. Fat fraction and total fat volume in the surrounding UAW structures increased after 16 weeks of FP by 20.6% and 15.4%, respectively; BMI and neck sizes did not seem to change ( Table 6 ). These subjects, on average, showed no change in Pcrit (mean change ± SE: 0.13 ± 0.81 cm H 2 O), and an apparent improvement in asthma control as seen in FEV 1 % predicted (6.33 ± 3.84) and in ACQ scores (-0.50 ± 0.42) was seen. None of these subjects reported nocturnal nasal congestion either at baseline or at their repeat visit. Tongue strength increased (anterior 3.67 ± 2.85; posterior 5.00 ± 0.58 KPa), whereas endurance (Ttot) subsided particularly at anterior location (anterior -16.00 ± 25.58; posterior -2.33 ± 17.57 seconds). With the exception of significantly increased posterior tongue strength (p = 0.01), none of the changes in these parameters reached statistical significance, likely a result of the small sample size.
Results for the Run-Out Phase
Per protocol, at the last visit of the treatment phase (V5), all subjects had their FP reduced to half (880 mcg/day) for the ensuing 2 weeks. Only 11 (61%) of subjects had been tapered off FP by study completion. Overall dose adherence was not significantly different for the run-out relative to the treatment period (88.1% ± 2.7% vs. 91.2% ± 1.7%, p = 0.21). The percent reduction in the cumulative FP dose used throughout run-out, relative to the treatment period was 87.8% ± 1.3%.
Changes in asthma and outcome variables measured during run-out relative to the treatment period, with adjustment for percent reduction in cumulative FP dose are shown in the supplemental material (Table S3) . On average, as the subjects shifted from the treatment to the run-out period, asthma control was maintained. Likewise, tongue function changes persisted and scores on the sleep questionnaires and anthropometrics remained not significantly changed.
DISCUSSION
Summary of Findings
This is the first study to test the effects of an orally inhaled corticosteroid on UAW during sleep and wakefulness. After 16 weeks of high-dose FP treatment: (1) Pcrit overall improved Following treatment, overall the Pcrit significantly improved on average (p = 0.04). However, variability in the response was noted, as some subjects improved (Pcrit became more negative), others remained unchanged and others deteriorated (Pcrit became less negative). Data are presented as mean ± standard error (SE).
( Figure 3 , Table S2 ); (2) the individual response was dependent upon each subject's baseline characteristics, with older age, male gender and worse asthma control predicting a Pcrit deterioration ( ( Table 6 ). These findings suggest UAW responses to FP are dependent upon baseline characteristics, and determined by concomitant but reciprocally counteracting local and lower airway changes.
Patterns of Pcrit Responses to FP Therapy and Possible Explanations
We observed an overall improvement (more negative) in Pcrit with orally inhaled FP for 16 weeks. Although somewhat surprising, this observation provided us an opportunity to get more insight into the dynamic influences of FP on upper and lower airway function, as not all subjects responded the same, i.e., some improved, some remained unchanged and some deteriorated. These changes might not occur randomly but rather relate to various degrees of synchronous changes in the forces that regulate the upper airway patency during sleep 32, 33 :
(1) an improvement in UAW collapsibility may result from anti-inflammatory effects of FP, in the nose and in the lower airways. It is known that increased nasal resistance results in more negative intrapharyngeal pressure during inspiration which predisposes to oropharyngeal collapse. 34 It is possible that FP via either a topical effect (propulsion of residual particles to the nose, via mucociliary clearance) or systemic absorption 14 may have attenuated the nasal inflammation, and thereby the nasal resistance. Meanwhile, the improved lower airways obstruction, as suggested by asthma control indices including spirometric measures (Tables 3 and 5) would unload the UAW. During nocturnal asthma, the forced inspiration accentuates the negative intraluminal pressure, "sucking closed" the deformable UAW. 35 Additionally, the active contraction of the respiratory muscles during forced expiration could increase the pressure in the UAW surrounding tissues, causing the airway to collapse. 36, 37 The observed improvement in lung mechanics could attenuate these effects, decreasing the Pcrit. Secondly, it could reduce the degree of hyperinflation, since resistance to airflow is inversely related to lung volumes. 38 Patients with nocturnal asthma, who start the night hyperinflated relative to controls, experience an augmented decline in functional residual capacity (FRC) to levels comparable to those of control subjects during REM sleep. 39 It is thus possible that the improved lung mechanics with FP also attenuated the degree of decline in FRC during sleep; the resultant increase in pharyngeal UAW tethering via tracheal tug could have rendered it stiffer, 40 thereby also improving the Pcrit. Further studies accounting for nasal resistance and sleep related changes in lower airway mechanics will be needed; (2) an unchanged Pcrit could result from above changes being offset by deleterious effects, discussed next; (3) a deterioration in Pcrit could result from a predominant increase in the surrounding tissue pressure, including fat accumulation, and from changes in the properties of UAW muscle, as suggested by our findings on the tongue discussed below. As shown by our MRI data ( Table 6) , FP may cause regional fat redistribution around the UAW, probably as a result of systemic absorption which has been shown particularly with the highly lipophilic fluorinated compounds.
14,41 And then, why did our subjects show different responses to the same treatment? The outcome might be determined yet by an interaction with several baseline predictors.
Predictors of Pcrit Response to FP
We observed a relationship of Pcrit response with age, such that older age (only 36 years on average!) was a predictor of Pcrit deterioration (Table 4) . Likewise, male gender predicted Pcrit deterioration, while none of those young females with stiff UAW seemed deleteriously affected by FP. There is clear recognition of male gender predominance of OSA and that women, while protected when premenopausal (as all our female patients were), catch up in OSA risk at menopause 42 ; however, why men unfortunately suffer a "double hit" when exposed to FP, and how the many asthmatic women on ICS change around the menopause remains to be studied. Also, baseline asthma control, defined by ACQ score-a composite measure that includes daytime and nighttime symptoms-related to worsening Pcrit (Table 4 ). These observations suggest the UAW of older, male, and of those individuals with less controlled asthma may be more prone to detrimental FP effects. The lack of significant associations of Pcrit response with other demographics (BMI, neck size), baseline PSG and spirometric measures does not negate their potential role (especially as trends already emerged- Table 4) , and rather reflects small sample size Table 6 -Changes from baseline with FP treatment in fat content around the UAW structures, anthopometrics, Pcrit, asthma control indices, and tongue measures in the three subjects studied with MRI. and variability inherent to human physiology and differences between sleep vs. wakefulness lung measures, which could be better understood in larger studies.
Changes in the Tongue Function in Response to FP Therapy and Possible Mechanisms
FP increased tongue strength and reduced its endurance (Figures 4 and 5, Table S2 ), which persisted during the run-out period (Table S3) . We believe a dual effect underlies these findings: (1) the improved strength may be related to some degree of transient muscle fiber hypertrophy. Tongue hypertrophy has been reported in children treated with ICS, 43, 44 as soon as 4-7 weeks into treatment. 44 This effect is believed to be partly due to muscle fiber hypertrophy 43, 44 ; (2) the reduced endurance could reflect incipient functional deficits, building-up as a result of differential effects on the tissue compartments comprising the tongue, such as (a) unmasked preexistent inflammation-induced remodeling/dysfunction, and/or (b) a direct drug effect on the muscle fibers. Patients with asthma frequently have UAW inflammation, which often extends distally to the pharyngeal area. Inflammation in the pharyngeal UAW has been linked to profibrotic cytokines and collagen deposition. 45 Collectively, these observations suggest that sustained inflammation leads to UAW remodeling which could adversely affect tissue compliance and/or its mechanical coupling, translating into impaired ability to sustain increased demands. 45 How ICS impact the structure and function of skeletal muscles, such as those of the pharyngeal UAW, remains to be studied. However, a myopathic effect of the vocal cords adductors is believed to underlie the bowing of the vocal cords on phonation observed in patients with ICS-induced dysphonia. 13 In the only prospective study to date, such an effect on this small muscle developed in 7-12 weeks, was dose-dependent, resolved in one month, but resumed with reinitiating the drug. 13 This finding may mirror other UAW muscles alterations in response to our intervention with FP. Interestingly, a more recent study of untreated OSA patients reported a pattern of wakefulness tongue function changes 46 similar to that observed in our study, i.e., these patients, relative to controls, demonstrated greater maximal protrusive force but shorter time to task failure. These functional alterations have as histological substrate a shift from type I (slow twitch-low force, fatigue resistant) to type II (fast twitch-high force, fatigue prone) muscle fibers, 47, 48 and are believed to be an adaptive mechanism to the increased contractile demands on the dilator. 46 Was a similar pathology involved in our subjects? Further work needs to be done to answer this question.
Possible Long-Term Interactions of FP Effects
We only investigated the UAW collapsibility at a point when subjects had received 16 weeks of ICS treatment, which is relatively short comparing to clinical practice where this therapy is usually chronic, in some cases lifelong. Corroborating with the overall effects on the tongue (Figures 4 and 5) and their lack of an association with Pcrit responses (Tables 4 and 5) , and the fat accumulation observed in the 3 subjects (Table 6 ) lends us to speculate that, in time, the pharyngeal UAW patency may overall shift towards a detrimental pattern with important clinical implications, such that: (1) short-term, anti-inflammatory effects and transient muscle fiber hypertrophy may predominate, and these "protective processes" maintain the UAW patent. However, fiber atrophy and shifts in the type of fibers comprising the genioglossus (and possibly other UAW dilators), along with surrounding UAW fat, concomitantly start to build-up, resulting in some functional deficits as observed in the present study; and (2) long-term, these "non-protective processes" along with the airway remodeling, may eventually take a more prominent role overall, rendering the muscle less efficient to compensate when faced with increased demands particularly during sleep, setting the stage for SDB/OSA. Additionally, these latter changes could have implications for other UAW functions, such as mastication and deglutition, functions of particular importance to the respiratory patient.
Limitations of the Study
Despite our study's novelty, we acknowledge a number of limitations. First, we were unsuccessful at securing placebo MDI, and the lack of a control group raises the possibility that our findings may reflect natural history of UAW in asthma. However, we doubt that this encompasses spontaneous improvement in UAW mechanics over four months. Furthermore, the night-to-night variability in passive Pcrit measurement has been shown to be nonsignificant, 28 such that, we believe the Pcrit changes we observed are due to the FP intervention. Additionally, we note that, albeit at a lower dose, FP has been continued throughout run-out in nearly half of subjects; although the LSE changes may seem to have continued during this phase (Table S3) , their magnitude was less than that achieved during the treatment (Table S2) , and not significantly different from the treatment period (Table S2) . These observations indicate that the ICS dose used during run-out may have been sufficient to maintain the tongue functional changes, and perhaps, once established, the FP effect may no longer be dosedependent. Certainly, future studies should step up the efforts for randomizing to a placebo or other control group. Second, the characteristics of the sample, with a narrow range of critical demographics, i.e., age, BMI, and "healthy" baseline characteristics (Pcrit, ACQ and FEV 1 ), precludes extension of these findings to asthma subjects who are older, male, heavier, and have less controlled asthma and physiology, and who are also more likely to receive ICS therapy. Our subgroup data, albeit small, suggest these patients are most vulnerable to detrimental UAW effects. Further studies including a wider range of such characteristics, will be needed. Third, we recognize that four months of therapy is relatively brief considering the prolonged duration of treatment that is generally provided to patients with asthma suffering from chronic airway inflammation. Thus, we can only speculate and refrain from drawing any firm conclusions regarding what many years of ICS therapy may do to the pharyngeal UAW. The duration of treatment may prove to be important in this interaction. It may also explain the somewhat discrepant previous dose-dependent association of ICS with habitual snoring and OSA risk noted in a clinic-based sample, 12 where ICS exposure may have been much longer than the four months tested in this study. We certainly encourage longer-term studies to assess these effects and underlying mechanisms. Last, the clinical impact of these changes on severity of SDB was not tested. Thus, gaining understanding of clinical significance of these physiologic and anatomic findings remains an interesting area of investigation. Despite these limitations, this initial pilot study opens the door for an array of clinical and mechanistic investigations. Such studies will be most feasible with multicenter efforts, owing to the inherent challenges to recruitment in sufficient numbers of subjects suitable for this kind of research.
In summary, this first, short-term study of otherwise healthy, young subjects with mild asthma and stiff UAW, suggests responses in the UAW collapsibility during sleep may be dependent upon baseline characteristics, and underlined by anti-inflammatory, direct tissue/muscle effects, and fat redistribution to the neck. We wish to caution that no firm conclusions can be drawn from these data; however, they are intriguing enough to lay the foundation for future larger and longer studies including patients with wider range of important baseline characteristics and detailed upper and lower airway assessments, to better understand these effects, as well as their long-term impact on OSA risk and other UAW functions. 
ABBREVIATIONS
METHODS
Subject Inclusion and Exclusion Criteria
Subjects with an asthma diagnosis were enrolled. This diagnosis was confirmed either by bronchodilator reversibility (≥ 12% improvement in FEV 1 following 2 puffs of albuterol) or a provocative concentration of methacholine needed to produce a 20% fall in FEV 1 (PC20) ≤ 8 mg/mL. Subjects had symptoms consistent with National Asthma Education and Prevention Program (NAEPP) asthma severity step ≥ 2, 1 and an FEV 1 ≥ 60% predicted.
Exclusion criteria included: 1) use of inhaled corticosteroid for > 2 weeks at a time during the prior 6 months, or any use in the last 6 weeks; 2) any oral or systemic corticosteroid use in the last 6 months; 3) as needed use of nasal steroids in the prior 6 months; 4) recent exacerbation or respiratory tract infection; 5) diagnosed osteopenia or osteoporosis; 6) unstable medical or psychiatric illness; 7) BMI > 40 kg/m 2 ; 7) treated OSA or new diagnosis of OSA (obstructive apnea index [OAI] > 10 events/h or desaturation < 70% on PSG); 8) established diagnosis of neuromuscular disease; 9) medications affecting breathing control; 10) current smoking or overall tobacco use ≥ 10 pack-years.
Step-Down Schedule in the Inhaled Fluticasone Propionate (FP) Dose during the Run-Out Period
At the end of 16-week treatment phase, in all subjects, the FP dose was reduced to 880 mcg/day. Subjects continued this dose for the following 2 weeks. Thereafter, the doses were further adjusted based on the ACQ score, using the validated cutoffs for level of control. 2 At the 2-week phone-call, the dose was adjusted based on the score on ACQ (version with symptoms and rescue bronchodilator use) 3 administered via phone, according to the following schedule: (1) if ACQ was ≤ 0.75, the FP was discontinued; (2) for ACQ > 0.75 and < 1.5, the FP dose was reduced to 440 mcg/day; (3) for ACQ ≥ 1.5, the FP 880 mcg/day was maintained. These doses were prescribed for the reminder of the study.
At the exit visit (V6), the dose was adjusted based on full ACQ (symptoms, rescue bronchodilator use and FEV 1 %) and subjects were transitioned to clinical care. 4 For those who had been off FP and remained well controlled (ACQ ≤ 0.75) at this visit, no further therapeutic steps were taken. For those in whom FP had not been discontinued during run-out, if at V6: (1) control has been maintained (ACQ ≤ 0.75), no FP was prescribed; (2) ACQ > 0.75 and < 1.5, FP 440 mcg/day was prescribed; and (3) ACQ remained ≥ 1.5, the FP was maintained/changed to 880 mcg/day.
Experimental Set-Up for Sleep Studies
Nocturnal polysomnogram (PSG) was obtained only at baseline (V2), for the purpose of evaluating subjects' eligibility. It was recorded on Grass Technologies systems (Astro-Med, Inc., West Warwick, RI), following standard criteria. 5 The montage included electroencephalogram (F3-A2, F4-A1, C3-A2, C4-A1, O1-A2, and O2-A1), bilateral electroculograms, bipolar chin and anterior tibialis electromyograms, 2 electrocardiographic (ECG) leads, snore microphone, nasal and oral airflow (thermocouples), nasal pressure cannula (Pro-Tech, Woodinville, WA), thoracic and abdominal excursions (Pro-Tech zRIP system, Pro-Tech Services, Inc., Mukilteo, WA), and finger oximetry.
For Pcrit studies, we used a previously described set-up, 6 with the exception that subjects wore a tight-fitting nasal mask (Respironics, Inc., Murrysville, PA) connected to a modified CPAP device (Respironics Inc. Murrysville, PA) that delivered both negative and positive (-20 to 20 cm H 2 O) pressures. For each subject, the same mask was applied with each study. If mouth breathing occurred, this was further prevented by sealing the mouth with waterproof tape. To prevent rebreathing, a leak was induced by inserting a leak valve in series above the pneumotachometer. Prior to each study, oxymetazoline hydrochloride 0.05%, 2 sprays in each nostril, was applied to reduce nasal congestion, and as previously reported, zolpidem 10 mg was administered to facilitate sleep and to suppress arousals. 6 To assure comparable conditions, for each subject, the same nasal and hypnotic treatments were administered at the post-treatment study. A recent study with a benzodiazepine systemic sedative (midazolam) demonstrated similar Pcrit measurements during natural and drug-induced sleep (-0.82 ± -3.44 and -0.97 ± -3.21 cm H 2 O, p = 0.663), which were highly associated (intraclass correlation coefficient = 0.92; 95% confidence interval, 0.78-0.97, p < 0.001), and both measurements similarly correlated with obstructive sleep apnea severity. 7 We measured Pcrit during stable N2 and N3 sleep, as we previously reported, 6 and also in light of the fact that a previous study has shown no significant influences of N2 vs. slow wave sleep on Pcrit. 8 Measurements were obtained with the subject supine, and the head in a contoured pillow to assure constant position.
Experimental Protocol for Pcrit Studies
As in our previous report, 6 CPAP was incremented by 1 cm H 2 O/min during stable NREM sleep, to eliminate flow limitation. This (holding) pressure was maintained or adjusted as necessary during the study. Following 5 min of stable N2-N3 sleep, the nasal pressure was lowered during exhalation by 1 cm H 2 O for 5-6 breaths, and then returned to the holding pressure for one minute before dropping to the next lower level. We repeated this sequence until airflow ceased (Pcrit) or arousal occurred. Another set of measurements was then taken by gradually increasing the mask pressure from Pcrit (i.e., Pcrit+1; Pcrit+2 cm H 2 O), back up to initial pressure drop. 9 Multiple trials were attempted in each subject, each night. 
Lingual Strength and Endurance (LSE) Assessment
Measurements were performed as previously published, 10 using the Iowa Oral Performance Instrument (IOPI) (IOPI Medical LLC, Carnation, WA). In brief, the IOPI has a standard-sized air-filled polymer balloon, called tongue sensor or bulb, which is inserted between the tongue blade and the roof of the mouth. The tube is connected by a tube to the IOPI device. The pressure generated (measured in KiloPascals) is displayed on a large, easy to read vertical array of colored light-emitting diodes (LED) screen. During endurance testing, visual feedback is provided to subjects by these Supplemental Material lights which signify linear increments, such that the uppermost red light represents the maximum pressure boundary, and the middle green light represents 50% of the pressure scale. Subjects were seated upright with the torso and neck erect. Measurements at the anterior (operationally defined as 10 mm posterior to the tongue tip) and posterior (operationally defined as 10 mm anterior to the most posterior circumvallate papilla) portions of the tongue ( Figure S1 ) 11 were obtained, to account for regional differences in tongue muscle composition, marked by a greater percentage of muscle tissue in the posterior tongue.
For tongue strength, subjects were asked to "press your tongue against the bulb as hard as possible…push, push, push." Sets of 3 trials were collected, first at anterior tongue location, and subjects were allowed to rest approximately 30 sec between trials. Subject's maximum pressure (Pmax) was identified as the highest value from 2 sets with the averages of the sets differing by ≤ 5%, to account for natural variability. If the trials were not within 5% of each other, further trials were allowed until 2 values within 5% were to be produced. The average (± SE) number of trials performed across all visits was 2.3 ± 0.1 and 2.6 ± 0.2, at anterior and posterior locations, respectively; no subject required more than 4 trials at each location, on any of the study visit.
After the tongue strength was determined, the bulb was repositioned to the anterior tongue to measure its endurance. Tongue endurance was defined as the time (in seconds) that subject maintained 50% of the Pmax. The maximum pressure on IOPI was set to the Pmax obtained at each location during Figure S1 -Positioning of the IOPI air-filled bulb at the anterior and posterior tongue locations.
Reproduced from Robbins J, et al. 11 with permission from The American Congress of Rehabilitation Medicine. that session, such that the middle green LED on the IOPI was programmed to represent the target 50% value. Subjects were read each time to "press your tongue against the bulb keeping the green light on as long as possible. As soon as you drop below the green light, stop pressing and relax." Three trials separated by 30 seconds of rest were obtained at each location.
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Magnetic Resonance Imaging (MRI)
Iterative decomposition of water and fat with echo asymmetry and least squares estimation fast spin-echo (IDEAL-FSE) is a chemical shift based fat-water separation method our group has developed to delineate fat-containing anatomy. As compared with conventional MRI, this technique provided robust water-fat separation in multiple regions of the body, including in the head, neck, and tongue. [13] [14] [15] [16] [17] The method acquires three images at slightly different echo times and uses an iterative algorithm to estimate the local inhomogeneity in the magnetic field. Phase shifts created by the field inhomogeneity are then demodulated from the three images and finally, a least squares pseudoinverse operation is performed to make final estimates of water and fat, free from the effects of field inhomogeneities. The separated water and fat images are perfectly co-registered and can be recombined into "in-phase" (water+fat), and "out-of-phase" (water-fat) images. Separate fat fraction axial images are then computed for T2-weighted IDEAL images.
Scans were acquired on a 3.0 Tesla MR750 scanner (GE Healthcare, Waukesha, WI) with an 8-channel neurovascular phased array coil. Sagittal and axial T1 and T2 end-expiratory gated images were obtained with a 4.0-mm thickness (and Table S3 -Changes in scores on asthma control indices, sleep questionnaires, tongue measures, and anthropometrics during the run-out relative to the treatment period 
